 Haemopoietic growth factors availability recombinant haemopoietic growth factors precise vitro experiments human vivo studies general results accord expectations previous vitro studies clinical exploitation haemopoietic growth factors great promise careful studies value effects growth factors multiple complex improvements blood cell counts se beneficial patient circumstances controlled trials clinical end-points essential situation chemotherapy-induced neutropenia large studies improvement mortality morbidity field cancer therapy major benefit haemopoietic growth factors dosage escalation consequent improvement response rate long-term survival careful patient selection large multicentre trials likely studies development severe thrombocytopenia effective means elusive thrombopoietin possibility haemopoietic growth factors adjunct treatment severe infections trial possibility fraught difficulties studies date use single factors beginning use factors synergistic combinations efficacy toxicity